Literature DB >> 24876383

Conserved allosteric hot spots in the transmembrane domains of cystic fibrosis transmembrane conductance regulator (CFTR) channels and multidrug resistance protein (MRP) pumps.

Shipeng Wei1, Bryan C Roessler1, Sylvain Chauvet1, Jingyu Guo2, John L Hartman2, Kevin L Kirk3.   

Abstract

ATP-binding cassette (ABC) transporters are an ancient family of transmembrane proteins that utilize ATPase activity to move substrates across cell membranes. The ABCC subfamily of the ABC transporters includes active drug exporters (the multidrug resistance proteins (MRPs)) and a unique ATP-gated ion channel (cystic fibrosis transmembrane conductance regulator (CFTR)). The CFTR channel shares gating principles with conventional ligand-gated ion channels, but the allosteric network that couples ATP binding at its nucleotide binding domains (NBDs) with conformational changes in its transmembrane helices (TMs) is poorly defined. It is also unclear whether the mechanisms that govern CFTR gating are conserved with the thermodynamically distinct MRPs. Here we report a new class of gain of function (GOF) mutation of a conserved proline at the base of the pore-lining TM6. Multiple substitutions of this proline promoted ATP-free CFTR activity and activation by the weak agonist, 5'-adenylyl-β,γ-imidodiphosphate (AMP-PNP). TM6 proline mutations exhibited additive GOF effects when combined with a previously reported GOF mutation located in an outer collar of TMs that surrounds the pore-lining TMs. Each TM substitution allosterically rescued the ATP sensitivity of CFTR gating when introduced into an NBD mutant with defective ATP binding. Both classes of GOF mutations also rescued defective drug export by a yeast MRP (Yor1p) with ATP binding defects in its NBDs. We conclude that the conserved TM6 proline helps set the energy barrier to both CFTR channel opening and MRP-mediated drug efflux and that CFTR channels and MRP pumps utilize similar allosteric mechanisms for coupling conformational changes in their translocation pathways to ATP binding at their NBDs.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC Transporter; Allosteric Regulation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator (CFTR); Ion Channel; Molecular Dynamics; Multidrug Transporter

Mesh:

Substances:

Year:  2014        PMID: 24876383      PMCID: PMC4106314          DOI: 10.1074/jbc.M114.562116

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  T-Coffee: A novel method for fast and accurate multiple sequence alignment.

Authors:  C Notredame; D G Higgins; J Heringa
Journal:  J Mol Biol       Date:  2000-09-08       Impact factor: 5.469

Review 2.  The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding.

Authors:  Suresh V Ambudkar; In-Wha Kim; Di Xia; Zuben E Sauna
Journal:  FEBS Lett       Date:  2005-12-22       Impact factor: 4.124

3.  Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein 1.

Authors:  Lei Qin; Jimin Zheng; Caroline E Grant; Zongchao Jia; Susan P C Cole; Roger G Deeley
Journal:  Biochemistry       Date:  2008-12-30       Impact factor: 3.162

4.  Identification of a region of strong discrimination in the pore of CFTR.

Authors:  N A McCarty; Z R Zhang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-10       Impact factor: 5.464

5.  The First Nucleotide Binding Domain of Cystic Fibrosis Transmembrane Conductance Regulator Is a Site of Stable Nucleotide Interaction, whereas the Second Is a Site of Rapid Turnover.

Authors:  Luba Aleksandrov; Andrei A Aleksandrov; Xiu-Bao Chang; John R Riordan
Journal:  J Biol Chem       Date:  2002-02-22       Impact factor: 5.157

6.  The CFTR ion channel: gating, regulation, and anion permeation.

Authors:  Tzyh-Chang Hwang; Kevin L Kirk
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

7.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.

Authors:  Robert B Best; Xiao Zhu; Jihyun Shim; Pedro E M Lopes; Jeetain Mittal; Michael Feig; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-07-18       Impact factor: 6.006

8.  Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces.

Authors:  J-P Mornon; P Lehn; I Callebaut
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

9.  Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4).

Authors:  Azza A K El-Sheikh; Jeroen J M W van den Heuvel; Elmar Krieger; Frans G M Russel; Jan B Koenderink
Journal:  Mol Pharmacol       Date:  2008-07-08       Impact factor: 4.436

10.  Accurate, precise modeling of cell proliferation kinetics from time-lapse imaging and automated image analysis of agar yeast culture arrays.

Authors:  Najaf A Shah; Richard J Laws; Bradley Wardman; Lue Ping Zhao; John L Hartman
Journal:  BMC Syst Biol       Date:  2007-01-08
View more
  11 in total

1.  Long-range coupling between the extracellular gates and the intracellular ATP binding domains of multidrug resistance protein pumps and cystic fibrosis transmembrane conductance regulator channels.

Authors:  Shipeng Wei; Bryan C Roessler; Mert Icyuz; Sylvain Chauvet; Binli Tao; John L Hartman; Kevin L Kirk
Journal:  FASEB J       Date:  2015-11-25       Impact factor: 5.191

2.  Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization.

Authors:  P Andrew Chong; Patrick J Farber; Robert M Vernon; Rhea P Hudson; Anthony K Mittermaier; Julie D Forman-Kay
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

Review 3.  Transformative therapies for rare CFTR missense alleles.

Authors:  Kathryn E Oliver; Sangwoo T Han; Eric J Sorscher; Garry R Cutting
Journal:  Curr Opin Pharmacol       Date:  2017-10-13       Impact factor: 5.547

Review 4.  Molecular modelling and molecular dynamics of CFTR.

Authors:  Isabelle Callebaut; Brice Hoffmann; Pierre Lehn; Jean-Paul Mornon
Journal:  Cell Mol Life Sci       Date:  2016-10-07       Impact factor: 9.261

Review 5.  Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy.

Authors:  Carlos M Farinha; Isabelle Callebaut
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

6.  Substitution of Yor1p NBD1 residues improves the thermal stability of Human Cystic Fibrosis Transmembrane Conductance Regulator.

Authors:  B M Xavier; E Hildebrandt; F Jiang; H Ding; J C Kappes; I L Urbatsch
Journal:  Protein Eng Des Sel       Date:  2017-10-01       Impact factor: 1.650

7.  Obligate coupling of CFTR pore opening to tight nucleotide-binding domain dimerization.

Authors:  Csaba Mihályi; Beáta Töröcsik; László Csanády
Journal:  Elife       Date:  2016-06-21       Impact factor: 8.140

8.  The molecular evolution of function in the CFTR chloride channel.

Authors:  Daniel T Infield; Kerry M Strickland; Amit Gaggar; Nael A McCarty
Journal:  J Gen Physiol       Date:  2021-10-14       Impact factor: 4.000

9.  The gut efflux pump MRP-1 exports oxidized glutathione as a danger signal that stimulates behavioral immunity and aversive learning.

Authors:  Jonathan Lalsiamthara; Alejandro Aballay
Journal:  Commun Biol       Date:  2022-05-05

10.  Investigating the Role of the Host Multidrug Resistance Associated Protein Transporter Family in Burkholderia cepacia Complex Pathogenicity Using a Caenorhabditis elegans Infection Model.

Authors:  Pietro Tedesco; Marco Visone; Ermenegilda Parrilli; Maria Luisa Tutino; Elena Perrin; Isabel Maida; Renato Fani; Francesco Ballestriero; Radleigh Santos; Clemencia Pinilla; Elia Di Schiavi; George Tegos; Donatella de Pascale
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.